Pegasus Biotech Inc is a contract research organization (CRO) and consulting provider headquartered in PEI, Canada. It primarily serves companies developing vaccines, biopharmaceuticals, and DNA vaccines for human and animal health. Its website positions the company not as SaaS or enterprise software, but as an R&D outsourcing service centered on laboratory capabilities, scientific teams, and project delivery.
Its services cover analytical development, animal health vaccines, DNA vaccine development, and process development. On the analytical side, this includes cell-based assays, ELISA, qPCR, HPLC, particle size, viscosity, and pharmacopeia-compliant methods. On the process side, it covers upstream fermentation and cell culture, seed bank development, purification, formulation, and technology transfer. Its project workflow is divided into Discover, Develop, and Deploy: first identifying regulatory requirements and defining deliverables, then developing processes and methods, and finally validating methods as needed, transferring technology, and producing reports.
The website does not provide standard packages or a price list. Instead, pricing is project-based and tied to deliverables. It explicitly states that a project plan and pricing are established before project kickoff, making it more suitable for customers that need customized R&D services rather than buyers looking for ready-to-use, seat-based subscription software. Payment methods, contract terms, and SLA details are not disclosed.
Its strengths lie in a clear specialist focus, with particular emphasis on DNA vaccines, animal health products, and biopharmaceutical commercialization experience. Its facilities include secure CL1/CL2 laboratories, and the company states that its QMS is externally audited, with compliance experience related to EMA, CFIA, FDA, USDA, and USP/EP/JP standards. The limitations are also obvious: the website does not present an online platform, dashboard, API, third-party integrations, permission management, or cloud/self-hosted deployment information, so it cannot be evaluated as a productized SaaS offering by conventional SaaS criteria.
It is better suited to R&D companies that already have vaccine candidates or biologics projects and need to strengthen capabilities in analytical methods, process scale-up, low-COGS optimization, regulatory submissions, and technology transfer. For Chinese customers, website accessibility and cross-border payment options are unclear. If samples, contract R&D, and regulatory materials are involved, additional assessment will be needed around cross-border logistics, data/sample compliance, and time-zone communication. Alternatives may include large international CRO/CDMO providers or China-based biopharmaceutical and vaccine process development service providers.
β This review is compiled from public sources and does not constitute a purchase recommendation. Verify all facts on the vendor's official site. Verify on pegasusbio.com official site.
pegasusbio.com is an Canada SaaS Tools provider. TG4G tracks its product information, an overall rating of 6.0/10, and a China-accessibility score of Limited (proxy recommended). Click "Visit Official Site" to reach pegasusbio.com directly.